دورية أكاديمية
Plerixafor-based mobilization and mononuclear cell counts in graft increased the risk of engraftment syndrome after autologous hematopoietic stem cell transplantation
العنوان: | Plerixafor-based mobilization and mononuclear cell counts in graft increased the risk of engraftment syndrome after autologous hematopoietic stem cell transplantation |
---|---|
المؤلفون: | Le-Qing Cao, Qi Wen, Bo-Ning Liu, Zhen-Yu Zhao, Xiao-Hui Zhang, Lan-Ping Xu, Huan Chen, Yu Wang, Lu Yu, Feng-Rong Wang, Xiao-Jun Huang, Xiao-Dong Mo |
المصدر: | Blood Science, Vol 6, Iss 3, p e00190 (2024) |
بيانات النشر: | Wolters Kluwer Health, 2024. |
سنة النشر: | 2024 |
المجموعة: | LCC:Diseases of the blood and blood-forming organs |
مصطلحات موضوعية: | Diseases of the blood and blood-forming organs, RC633-647.5 |
الوصف: | Engraftment syndrome (ES) is one of the most common complications in the early phase after autologous hematopoietic stem cell transplantation (ASCT), and we aimed to evaluate the incidence and risk factors for ES patients receiving ASCT in the era of plerixafor-based mobilization. A total of 294 were enrolled, and 16.0% (n = 47) experienced ES after ASCT. The main clinical manifestations were fever (100%), diarrhea (78.7%), skin rash (23.4%), and hypoxemia/pulmonary edema (12.8%). Plerixafor-based mobilization was associated with higher counts of CD3+ cells, CD4+ cells, and CD8+ cells in grafts. In univariate analysis of the total cohort, age ≥60 years, receiving ASCT at complete remission (CR), higher number of mononuclear cell (MNC), CD3+ cell counts, CD4+ cells as well as CD8+ cells transfused and plerixafor-based mobilization were associated with ES after ASCT. Multivariate analysis showed that age ≥60 years (P = .0014), receiving ASCT at CR (P = .002), and higher number of MNC transfused (P = .026) were associated with ES in total cohort. In plasma cell disease subgroup, age ≥60 years (P = .013), plerixafor-based mobilization (P = .036), and receiving ASCT at CR (P = .002) were associated with ES. Patients with more risk factors had a higher risk of ES. The 1-year probabilities of relapse, non-relapse mortality, and survival were comparable between patients with and without ES. Thus, plerixafor-based mobilization may influence the composition of T lymphocytes in grafts and increase the risk of ES, particularly in patients with plasma cell disease. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 2543-6368 00000000 |
Relation: | http://journals.lww.com/10.1097/BS9.0000000000000190; https://doaj.org/toc/2543-6368 |
DOI: | 10.1097/BS9.0000000000000190 |
URL الوصول: | https://doaj.org/article/04d52360bcec4f709b64f0eb53dc1a1f |
رقم الأكسشن: | edsdoj.04d52360bcec4f709b64f0eb53dc1a1f |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 25436368 00000000 |
---|---|
DOI: | 10.1097/BS9.0000000000000190 |